Evidence map›Paper›PMID 39610113›Full record

ArticlePsychiatry and clinical neurosciences2025

Whole-genome sequencing analysis of Japanese autism spectrum disorder trios.

Sawako Furukawa, Itaru Kushima, Hidekazu Kato, Hiroki Kimura, Yoshihiro Nawa, Branko Aleksic, Masahiro Banno, Maeri Yamamoto, Mariko Uematsu, Yukako Nagasaki and 3 more

Abstract read
In one paragraph

Article in Psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. [Kallmann syndrome in a girl caused by a novelZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sawako FurukawaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0003-2558-5853
Itaru KushimaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0002-0018-5178
Hidekazu KatoDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroki KimuraDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshihiro NawaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Branko AleksicDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masahiro BannoDepartment of Psychiatry, Seichiryo Hospital, Nagoya, Japan.ORCID https://orcid.org/0000-0002-2539-1031
Maeri YamamotoDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Mariko UematsuDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yukako NagasakiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tomoo OgiDepartment of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan.
Norio OzakiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0002-7360-4898
Masashi IkedaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Funding

GlaxoSmithKline JapanHori Sciences and Arts FoundationJapan Agency for Medical Research and Development JP21km0405216Japan Agency for Medical Research and Development JP21wm0425007Japan Agency for Medical Research and Development JP22gm1410011Japan Agency for Medical Research and Development JP22tm0424222Japan Agency for Medical Research and Development JP23ak0101215Japan Agency for Medical Research and Development JP23ek0109678Japan Agency for Medical Research and Development JP23gm1910005Japan Society for the Promotion of Science 21H00194Japan Society for the Promotion of Science 21K07543Japan Society for the Promotion of Science 23KJ1112Novartis JapanSENSHIN Medical Research FoundationTakeda Pharmaceutical CompanyUehara Memorial Foundation
6 · The paper itself

Abstract

aimAutism spectrum disorder (ASD) is a genetically and phenotypically heterogeneous neurodevelopmental disorder with a strong genetic basis. Conducting the first comprehensive whole-genome sequencing (WGS) analysis of Japanese ASD trios, this study aimed to elucidate the clinical significance of pathogenic variants and enhance the understanding of ASD pathogenesis.

methodsWGS was performed on 57 Japanese patients with ASD and their parents, investigating variants ranging from single-nucleotide variants to structural variants (SVs), short tandem repeats (STRs), mitochondrial variants, and polygenic risk score (PRS).

resultsPotentially pathogenic variants that could explain observed phenotypes were identified in 18 patients (31.6%) overall and in 10 of 23 patients (43.5%) with comorbid intellectual developmental disorder (IDD). De novo variants in PTEN, CHD7, and HNRNPH2 were identified in patients referred for genetic counseling who exhibited previously reported phenotypes, including one patient with ASD who had profound IDD and macrocephaly with PTEN L320S. Analysis of the AlphaFold3 protein structure indicated potential inhibition of intramolecular interactions within PTEN. SV analysis identified deletions in ARHGAP11B and TMLHE. A pathogenic de novo mitochondrial variant was identified in a patient with ASD who had a history of encephalitis and cognitive decline. GO enrichment analysis of genes with nonsense variants and missense variants (Missense badness, PolyPhen-2, and Constraint >1) showed associations with regulation of growth and ATP-dependent chromatin remodeler activity. No reportable results were obtained in the analysis of STR and PRS.

conclusionCharacterizing the comprehensive genetic architecture and phenotypes of ASD is a fundamental step towards unraveling its complex biology.

Indexed as

Autism Spectrum DisorderIntellectual DisabilityWhole Genome SequencingAdolescentAdultChildChild, PreschoolDNA-Binding ProteinsDNA HelicasesEast Asian PeopleFemaleHumansJapanMalePhenotypePTEN PhosphohydrolaseCHD7 protein, humanDNA-Binding ProteinsDNA HelicasesPTEN PhosphohydrolasePTEN protein, humanautism spectrum disordergeneticsintellectual disabilityphenotypewhole‐genome sequencing

Identifiers

PMID39610113
PMCPMC11874045

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.